IGC Pharma Advances AI-Driven Alzheimer's Research and Treatment in Q1 2026

IGC Pharma's Q1 2026 Financial Results and Strategic Advancements

IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company, has reported its financial results for the first quarter of fiscal year 2026, ended June 30, 2025. The company, which leverages artificial intelligence to develop innovative treatments for Alzheimer's disease, has made significant strides in both its clinical trials and AI-driven diagnostic platform 1

1

Accelerated Progress in Alzheimer's Research

IGC Pharma's primary focus remains on its Phase 2 CALMA trial, which is evaluating IGC-AD1, a cannabinoid-based proprietary formulation designed to address agitation in Alzheimer's patients. The company reports accelerated progress in this trial, which targets a symptom affecting up to 76% of Alzheimer's patients 1

1

In parallel, IGC Pharma is advancing its non-cannabinoid platforms, TGR-63 and IGC-M3, through preclinical development. These platforms aim to address underlying disease modification in Alzheimer's, potentially offering a more comprehensive approach to treatment 1

1

MINT-AD: AI-Driven Alzheimer's Diagnostics

A key highlight of IGC Pharma's recent developments is the progress made with MINT-AD, their AI-driven physician's tool. MINT-AD is designed to identify and stratify Alzheimer's risk factors and predict cognitive decline. The company has increased the number of harmonized databases and improved its training algorithms, enhancing the tool's capabilities 1

1

MINT-AD represents a significant step forward in early Alzheimer's detection. Trained on over 100 harmonized global datasets, including cognitive scores, genomic markers, neuroimaging, and lifestyle factors, MINT-AD aims to detect Alzheimer's disease before symptoms emerge. This could potentially benefit over 400 million individuals with early Alzheimer's pathology who are at risk for the disease 2

2

Related Stories

Gain Therapeutics Reports Q2 2024 Financial Results and Provides Corporate Update

Cosmo Pharmaceuticals Reports Strong H1 2024 Performance, Confirms Full-Year Guidance

Biotech Companies IMUNON and Evaxion Report Q2 2024 Financial Results and Business Updates

Q2 2024 Financial Results: A Mixed Bag for Tech and Healthcare Companies

Financial Performance and Strategic Initiatives

For the quarter ended June 30, 2025, IGC Pharma reported a net loss of approximately $1.6 million or $0.02 per share, an improvement from the $2.3 million or $0.03 per share loss in the same period of the previous year. The company has also raised approximately $3.5 million through private placements and at-the-market offerings 1

1

IGC Pharma is implementing cost-cutting measures and reallocating resources to prioritize the completion of the CALMA Phase 2 trial and the implementation of MINT-AD. The company maintains an undrawn $12 million credit facility with O-Bank, providing additional financial flexibility 1

1

Recognition and Future Outlook

IGC Pharma's innovative approach to Alzheimer's research has garnered recognition in the scientific community. The company's Principal Scientist, Dr. Jagadeesh Rao, received a Best Researcher Award at the 11th Annual World Neuroscience Awards. Additionally, IGC Pharma presented multiple posters at the Alzheimer's Association International Conference in Toronto, showcasing new data on MINT-AD 1

1

Looking ahead, IGC Pharma aims to further reduce operating expenses by 10% to 15% in FY2026 through strategic realignment, AI integration, and management accountability. The company remains committed to delivering real-world impact for patients and caregivers while driving long-term value for shareholders 2

2

As IGC Pharma continues to advance its AI-driven approach to Alzheimer's diagnosis and treatment, it represents a notable example of how artificial intelligence is being leveraged to address complex health challenges and potentially transform patient care in the field of neurodegenerative diseases.